Last reviewed · How we verify
NCT05412277
VIA Disc Nucleus Pulposus Older Patients Pilot
NA trial testing VIA Disc Nucleus Pulposus Allograft in Degenerative Disc Disease in 21 participants. Participants enrolled and being followed up; not accepting new ones.
30 August 2024
Quick facts
| Lead sponsor | VIVEX Biologics, Inc. |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 21 |
| Start date | 17 October 2022 |
| Primary completion | 30 August 2024 |
| Estimated completion | 31 December 2024 |
| Sites | 5 locations across United States |
Drugs / interventions tested
- VIA Disc Nucleus Pulposus Allograft
Conditions studied
- Degenerative Disc Disease — all drugs for Degenerative Disc Disease →
- Low Back Pain — all drugs for Low Back Pain →
- Disc Degeneration — all drugs for Disc Degeneration →
Sponsor
VIVEX Biologics, Inc. — full company profile →
Who can join
65 and older, any sex, with Degenerative Disc Disease or Low Back Pain. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
VIA Disc NP is a non-surgical intervention intended to supplement the nucleus pulposus tissue in degenerated intervertebral discs.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Supplemental Nucleus Pulposus Allograft in Patients with Lumbar Discogenic Pain: Evaluation of Clinical Outcomes and Quality of Life in Medicare Beneficiaries.
Azeem N, Myers TJ, Tate JL, Gilmore CA, et al · · 2025 · cited 1× · PMID 40454303 · DOI 10.2147/cia.s523457
Verify or expand the search:
- PubMed search for NCT05412277
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Degenerative Disc Disease
Currently open trials in the same condition.
- NCT07254806 — A Study to Evaluate the Effectiveness of IDCT (Intradiscal Cell Therapy) in Subjects With One Level, Symptomatic Mild to · Phase 3 · recruiting
- NCT04679844 — Post Marketing Study of MagnetOs Easypack Putty Standalone Compared to Demineralized Bone Matrix or Fibers Mixed With Au · NA · recruiting
- NCT06704919 — Conduit Cages and Fibergraft BG Putty · recruiting
- NCT06053242 — Safety, Tolerability, and Effectiveness of Intramuscular Injection of CELZ-201-DDT for the Treatment of Chronic Lower Ba · Phase 1, PHASE2 · recruiting
- NCT03810573 — Evaluation of NB1 Bone Graft Following Lumbar Interbody Arthrodesis · NA · recruiting
Other VIVEX Biologics, Inc. trials
Trials by the same sponsor.
- NCT06345690 — VIA Disc NP Registry 3.0 · recruiting
- NCT05196191 — Wound Healing Following Penile Prosthesis Implant · NA · terminated
- NCT05201287 — VIA Disc NP Pilot for Patients With Symptomatic Degenerated Discs · NA · active not recruiting
- NCT04835389 — Study of AlloGen® Liquid Intra-articular Injection for Knee Osteoarthritis · Phase 1 · withdrawn
- NCT04652687 — VIA Disc NP Registry · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05412277 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by VIVEX Biologics, Inc.
- Last refreshed: 29 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05412277.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing